Read by QxMD icon Read

Bone scans in prostate cancer

Ofer Nathan Gofrit, Stephen Frank, Amichay Meirovitz, Hovav Nechushtan, Marina Orevi
AIM: Castrate-resistant prostate cancer (CRPC) often shows histological evidence of neuroendocrine differentiation (NED). To evaluate the extent of NED in patients with CRPC, we used PET/CT with Ga-[DOTA-Tyr]-octreotate (Ga-DOTA-TATE), a somatostatin analog that binds somatostatin receptor 2 with high affinity. This radiotracer is used in imaging of neuroendocrine tumors. METHODS: Twelve patients (mean age, 65 [SD, 12] years) with CRPC were studied. Their mean prostate-specific antigen level at scanning was 85...
October 21, 2016: Clinical Nuclear Medicine
Michael T McCarthy, Hawa Ebrahem, Zariena Aibdeen, Philip A Hodnett, Elizabeth Mulcahy, Nemer Osman
In prostate cancer patients, if bone scan demonstrates a solitary lesion in atypical area, this is possibly an indication of metastatic disease. Therefore, biopsy confirmation is required to determine the nature of the abnormality and therefore dictates further staging investigations and treatment options.
October 2016: JRSM Open
Tapas Das, Ajit Shinto, Koramadai Karuppuswamy Kamaleshwaran, Sharmila Banerjee
Radiochemical studies and biological evaluation in animal models have shown superior radiochemical properties and better clearance pattern for Lu-DOTMP compared with Lu-EDTMP, an agent recently proven to be efficacious and safe for metastatic bone pain palliation. This prompted us to initiate the clinical evaluation of Lu-DOTMP. The images represent the whole-body scans of a prostate cancer patient (man, 67 years) with skeletal metastases recorded after administering 3.7 GBq (100 mCi) of Lu-DOTMP.
October 5, 2016: Clinical Nuclear Medicine
Thorsten Derlin, Desiree Weiberg, Jan M Sohns
Paget disease is a chronic disorder resulting in enlarged and misshapen bones, and is caused by disorganized bone remodeling. We present the case of an 85-year-old man with prostatic adenocarcinoma and known Paget disease of the right iliac bone who underwent Ga-prostate-specific membrane antigen ligand, C-acetate, and F-fluoride PET/CT for restaging of cancer. On all PET scans, increased tracer accumulation was observed in Paget disease of bone. Besides that Paget disease may mimic metastases on PET/CT using various radiotracers, including Ga-prostate-specific membrane antigen ligands and C-acetate, this case highlights the potential of multiparametric disease characterization on PET...
October 5, 2016: Clinical Nuclear Medicine
Sanjoy Kumar Sureka, Ruchir Maheshwari, Shalini Agnihotri, Nilay Mitash, Shamim Ahmad, Anil Mandhani
BACKGROUND & OBJECTIVES: There is lack of data on natural history and progression of prostate cancer (PC) which have implications in the management of the disease. We undertook this retrospective study to analyze factors predicting progression of metastatic PC to castration-resistant prostate cancer (CRPC) in Indian men. METHODS: Complete records of 223 of the 489 patients with metastatic PC were obtained from computerized data based system in a tertiary care hospital in north India between January 2000 to June 2012...
May 2016: Indian Journal of Medical Research
Hojjat Ahmadzadehfar, Kambiz Azgomi, Stefan Hauser, Xiao Wei, Anna Yordanova, Florian Gaertner, Stefan Kürpig, Holger Strunk, Markus Essler
PURPOSE: We retrospectively evaluated the utility of (68)Ga-PSMA-11 PET for planning (223)RaCl2 therapy of patients with metastatic prostate cancer and its impact on the therapeutic response as determined by PSA and ALP, as well as the correlation of PSA changes with the results of PSMA-PET, follow-up scans. METHODS: Sixty-three patients with a median age of 73 years who underwent a total of 307 cycles of therapy with (223)RaCl2 were analyzed. In thirty-one patients bone scans and radiological imaging was performed for pre therapeutic imaging (group 1)...
September 22, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Randeep Kulshrestha, Sobhan Vinjamuri, Andrew England, Julie Nightingale, Peter Hogg
This article shall describe the role of (18)F-Sodium Fluoride ((18)F-NaF) PET/CT bone scanning in the staging of breast and prostate cancer. (18)F-NaF PET was initially utilised as a bone scanning agent in the 1960s and early 1970s, however its usage was restricted by the then available gamma cameras. The advent of hybrid PET/CT cameras in the late 1990s has shown a resurgence of interest in its usage and role. After a brief introduction, this paper will describe the radiopharmaceutical properties, dosimetry, pharmacokinetics, and mechanism of uptake of (18)F-NaF...
September 15, 2016: Journal of Nuclear Medicine Technology
Jordan A Holmes, Jeannette T Bensen, James L Mohler, Lixin Song, Merle H Mishel, Ronald C Chen
BACKGROUND: Meeting quality of care standards in oncology is recognized as important by physicians, professional organizations, and payers. Data from a population-based cohort of patients with prostate cancer were used to examine whether receipt of care was consistent with published consensus metrics and whether receiving high-quality care was associated with less patient-reported treatment decisional regret. METHODS: Patients with incident prostate cancer were enrolled in collaboration with the North Carolina Central Cancer Registry, with an oversampling of minority patients...
September 13, 2016: Cancer
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature...
August 31, 2016: European Urology
Masayuki Sano, Shinya Yamamoto, Sho Uehara, Takeshi Yuasa, Hitoshi Masuda, Iwao Fukui, Junji Yonese
Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usually limited. In addition, a complete response is quite rare. We herein present the case of a patient who achieved complete response from AWS, with the duration of this response lasting for >6 years. A 72-year-old man with metastatic prostate cancer received CAB with a luteinizing hormone-releasing hormone analog and bicalutamide...
September 2016: Molecular and Clinical Oncology
Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Marco Bandini, Patrizio Rigatti, Francesco Montorsi, Alberto Briganti
: In the absence of data from randomized trials, the role of local treatment in metastatic prostate cancer (PCa) is gaining interest. Our study aimed to assess perioperative and long-term oncologic outcomes of radical prostatectomy (RP) in a selected cohort of 11 patients with oligometastatic disease treated with RP and extended pelvic lymph node dissection between 2006 and 2011. Oligometastatic disease was defined as the presence of five or fewer bone lesions at bone scan with or without suspicious pelvic or retroperitoneal nodal involvement at preoperative imaging...
August 26, 2016: European Urology
Zachary S Zumsteg, Timothy J Daskivich, Howard M Sandler
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Arun Sasikumar, Ajith Joy, Raviteja Nanabala, M R A Pillai, Hari T A
65-year-old man with left-sided pelvic pain on evaluation was found to have features suggestive of either Paget disease or prostatic bone metastasis of the left hemipelvis based on Tc-MDP bone scan and MRI. Ga-PSMA PET/CT to assess the possibility of primary prostate cancer and if present to stage it helped to rule out prostate cancer because of absence of focal abnormal increased tracer uptake in the prostate gland. However, false-positive tracer uptake was noted in the left hemipelvis, which was subject to biopsy and histopathologically proven to be Paget disease involvement...
October 2016: Clinical Nuclear Medicine
Masato Yasui, Koichi Uemura, Shuko Yoneyama, Takashi Kawahara, Yusuke Hattori, Jun-Ichi Teranishi, Masahiro Inoue, Jun-Ichi Ohta, Yumiko Yokomizo, Masahiro Yao, Hiroji Uemura, Yasuhide Miyoshi
OBJECTIVE: In Japan, flutamide had been commonly used as second-line alternative antiandrogen hormonal therapy for metastatic castration-resistant prostate cancer that relapses after initial hormone therapy before new androgen pathway inhibitors became available. In this study, we attempted to identify predictive factors for efficacy of alternative antiandrogen as second-line hormone therapy. METHODS: We identified consecutive 65 patients with metastatic castration-resistant prostate cancer who were treated with alternative antiandrogen as second-line hormonal therapy (bicalutamide to flutamide)...
August 17, 2016: Japanese Journal of Clinical Oncology
Maisarah Mohamad, Norhazlina Abdul Wahab, Rosna Yunus, Nor Azian Abdul Murad, Zulkifli Md Zainuddin, Murali Sundaram, Norfilza Mohd Mokhtar
BACKGROUND: There is an increasing concern in the role of microRNA (miRNA) in the pathogenesis of bone metastasis (BM) secondary to prostate cancer (CaP). In this exploratory study, we hypothesized that the expression of vinculin (VCL) and chemokine X3C ligand 1 (CX3CL1) might be downregulated in clinical samples, most likely due to the posttranscriptional modification by microRNAs. Targeted genes would be upregulated upon transfection of the bone metastatic prostate cancer cell line, PC3, with specific microRNA inhibitors...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Colette A Whitney, Lauren E Howard, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Stephen J Freedland
BACKGROUND: Although race is associated with prostate cancer progression in early stage disease, once men have advanced disease, it is unclear whether race continues to predict a poor outcome. The authors hypothesized that, in an equal-access setting among patients with castration-resistant prostate cancer (CRPC) and no known metastases (M0/Mx), black men would receive imaging tests at similar rates as nonblack men (ie, there would be an equal opportunity to detect metastases) but would have a higher risk of metastatic disease...
August 9, 2016: Cancer
Jingjing Zhang, Gang Niu, Lixin Lang, Fang Li, Xinrong Fan, Xuefeng Yan, Shaobo Yao, Weigang Yan, Li Huo, Libo Chen, Zhiyuan Li, Zhaohui Zhu, Xiaoyuan Chen
: This study aims to document the first-in-human application of a (68)Ga-labeled heterodimeric peptide BBN-RGD (bombesin-RGD) that targets both integrin αvβ3 and gastrin releasing peptide receptor (GRPR). We evaluated the safety and assessed the clinical diagnosis value of (68)Ga- BBN-RGD positron emission tomography (PET)/x-ray computed tomography (CT) in prostate cancer patients in comparison with (68)Ga-BBN. METHODS: Five healthy volunteers (M 4, F 1, 28-53 y) were enrolled to validate the safety of (68)Ga-BBN-RGD...
August 4, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Montserrat Estorch Cabrera, Pablo Maroto Rey, Ignasi Carrió, Alberto Montes, Diego Alonso López
Painful bone metastases are common in prostate cancer, with current treatments including non-steroidal analgesics and opiates, surgery, external beam radiotherapy and bone-targeting β-emitting radiopharmaceuticals. The α-emitting isotope (223)Ra-dichloride (Ra-223) has been associated with improved overall survival and increased time to first skeletal-related events in patients with castration-resistant prostate cancer (CRPC) presenting with symptomatic bone metastases. The current study reports the case of a 70-year-old male patient, who was diagnosed with prostate cancer in 1999 upon presentation with increased prostate-specific antigen (PSA) levels and painful bone metastases in the context of CRPC...
August 2016: Oncology Letters
Christie Lin, Tyler J Bradshaw, Timothy G Perk, Stephanie Harmon, Jens Eickhoff, Ngoneh Jallow, Peter Choyke, William Dahut, Steven M Larson, John Laurence Humm, Scott Perlman, Andrea B Apolo, Michael J Morris, Glenn X Liu, Robert Jeraj
PURPOSE: (18)F-NaF, a positron emission tomography (PET) radiotracer of bone turnover, has shown potential as an imaging biomarker for assessing therapeutic response of bone metastases. This study aims to evaluate the repeatability of (18)F-NaF PET-derived SUV metrics in individual bone lesions from patients in a multicenter study. METHODS: Thirty-five metastatic castrate-resistant prostate cancer patients with multiple metastases received two whole-body (test-retest) (18)F-NaF PET/computed tomography (CT) scans 3±2 days apart from one of three imaging sites...
July 21, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Aseem Anand, Michael J Morris, Reza Kaboteh, Mariana Reza, Elin Trägårdh, Naofumi Matsunaga, Lars Edenbrandt, Anders Bjartell, Steven M Larson, David Minarik
RATIONALE: The effect of the procedural variability in image acquisition on the quantitative assessment of bone scan is unknown. Here, we have developed and performed pre-analytical studies to assess the impact of the variability in scanning speed and in vendor specific gamma-camera on reproducibility and accuracy of the automated bone scan index (BSI). METHODS: Two separate pre-analytical studies were performed. Patient-Study: To evaluate the effect on BSI reproducibility, repeat bone scans were prospectively obtained from metastatic prostate cancer patients enrolled in three groups (Grp)...
July 21, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"